电邮这篇文章 Efficiency of denosumab in giant cell tumor of the bone
- 作者: Semenov N1
-
隶属关系:
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
- 期: 卷 15, 编号 2 (2013)
- 页面: 54-56
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26908
- ID: 26908
如何引用文章
全文:
详细
Studies of the mechanisms of giant cell tumor of the bone have confirmed the pivotal role of the RANK-RANKL-OPG (receptor activator of nuclear factor kappa-b – receptor activator of nuclear factor kb ligand – osteopretegerin ligand) system and also shown that stromal cells (spindle-shaped fibroblasts) carry a tumor potential. The paper gives the results of 2 investigations of the novel monoclonal antibody denosumab, an osteoprotegerin analogue, in 199 patients with giant cell tumor of the bone. Both X-ray evaluation and morphological re-examination of the tumor revealed the high efficacy of denosumab, which was attended by normalization of enhanced osteolysis. It was shown that there was a possibility of performing the lower volume of surgery or postponing the latter to a later time in patients with a potentially operable tumor, without causing damage to them.
作者简介
N Semenov
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Email: niksemenov1969@yandex.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей
参考
- Zheng M.H, Robbins P, Xu J et al. The histogenesis of giant cell tuvour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297–307.
- Doussis I.A, Puddle B, Athanasou N.A. Immunophenotype of multinucleated and vononuclear cells in giant cell lesions of bone and soft tissue. J Clin Pathol 1992; 45: 398–404.
- Stepanova E, Semenov N, Lichinitser M. Expression of apoptotic and angiogenic factors on giant - cell tumor of bone. J Bone Miner Metab 2001; 19 (Suppl.): 54.
- Roudier M.P, Kellar-Graney K.L, Huang L.Y et al. RANK and RANKL expression in giant cell tumours of bone: an immunohistochemical study. 12 Annual Connective Tissue Oncology Society Meeting, 2006; Venice, Italy.
- Balke M et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134 (9): 969–78.
- Doncel-Cabot A, Gracia-Alegría I, Majó-Buigas J. Giant cell tumours. A review of experience over the last 19 years. Journal of Bone and Joint Surgery. British Volume; 86-B, Issue SUPP II: 131–2.
- Oda Y, Miura H, Tsuneyoshi M, Iwamoto Y. Giant Cell Tumor of Bone: Oncological and Functional Results of Long - term Follow - up. Jpn J Clin Oncol 1998; 28: 323–8.
- Zhen W, Yaotian H, Songjian L, Ge L et al. Giant - cell tumour of bone. The long - term results of treatment by curettage and bone graft. J Bone Joint Surg [Br] 2004; 86-B: 212–6.
- Thomas D, Henshaw R, Skubitz K et al. Denosumab in patients with giant cell tumour of bone: an open label phase 2 study. Lancet Oncol 2010; 11: 275–80.
- Blay J, Shawla S.P, Martin Broto J et al. Denosumab safety and efficacy in giant cell tumor of bone (GCTB): interim results from a phase 2 study. J Clin Oncol 2011; 29 (Suppl. 15): 10034.
- Branstetter D.G, Nelson S.D, Carlos Manivel J et al. Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant - Cell Tumor of Bone. Cancer Res 2012; 18 (16): 4415–24.
